aTyr Pharma said on October 27, 2026, that it will carry out a 1-for-40 reverse stock split intended to help the biotechnology company meet Nasdaq’s minimum bid price requirement. The aTyr reverse split is scheduled to take effect at 5 p.m. ET on October 28.

Key Takeaways

  • Split-adjusted trading is expected to begin on October 29 under the existing ATYR ticker.
  • The company expects outstanding shares to fall from approximately 100.5 million to approximately 2.5 million.

aTyr reverse split and Nasdaq trading

Every 40 issued and outstanding common shares will be combined into one share. The stock is expected to begin trading on a split-adjusted basis when the Nasdaq Capital Market opens on October 29, with a new CUSIP number of 002120301.

Shareholders approved the reverse split at a special meeting on October 16, and the board subsequently selected the 1-for-40 ratio. The company said the action is intended to bring it into compliance with Nasdaq’s minimum bid price requirement; regaining compliance is not assured.

The number of authorized common shares will remain at 340 million, and the par value per share will not change.

What happens to shareholder positions

aTyr said the split will affect common shareholders proportionally and generally will not change their percentage ownership, except where fractional-share treatment applies. No fractional shares will be issued: shareholders of record otherwise entitled to a fraction will have it rounded up to a whole share.

Positions held through banks, brokers or other nominees will be adjusted automatically, with no further action required from shareholders, subject to brokers’ processes. Equiniti Trust Company will act as exchange agent.

Outstanding stock options, restricted stock units and warrants will also be adjusted proportionally. Exercise prices for options and warrants will increase in proportion to the split, under their respective terms.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.